OPT: Opthea Corp Forward P/S Multiple

Corporate company logo of Opthea Corp (OPT)

Opthea Limited (OPT) collaborates with ophthalmology centers to test methods for combating macular degeneration. The projected P/S multiple demonstrates valuation dynamics, with the indicator holding at 5776.30. High-quality Australian management ensures the transparency of trials. FDA approval of the unique drug will allow Opthea Limited (OPT) to exercise pricing power over the therapy, complementing existing market blockbusters.

opthea.com - OPT Market Cap to Future Revenue Ratio (period 07/04/2022 - 06/28/2025)

Comprehensive metric breakdowns and analytics for Opthea Corp (OPT)

- stock price and consensus target price:
Stock Quotes Opthea|OPT - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Opthea Corp|OPT - Value Adjusted for Debt and Cash
- issuer book value statistics:
Book Value per Share Opthea|OPT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio opthea.com|OPT - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Opthea Limited|OPT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Opthea Limited|OPT - Company Debts|Debts to Book Capitalization Opthea Corp|OPT - Long-Term Debt Volume|Company Short-Term Debt Opthea|Quick Ratio opthea.com
- financial results and valuation multiples details:
OPT - Net Financial Result|Future Profit Opthea Limited|OPT - Market Price to Net Income Ratio|Forward P/E Multiple Opthea Ltd.|OPT - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Opthea Corp|OPT - Operating profit before amortization|Earnings per share for the last twelve months Opthea|OPT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months opthea.com|OPT - Earnings per share trend in current year|Expected earnings per share growth for next year Opthea Limited
- revenue and sales details:
OPT - Company Total Sales|Company Projected Revenue Opthea|OPT - Price-to-Sales Ratio|Forward P/S Multiple Opthea Corp
Summary company analytics:Opthea OPT
Manufactured products of Opthea Limited

For Opthea Limited, which focuses on developing treatments for macular degeneration, an analysis of forward EV/Revenue allows for an assessment of market expectations regarding future investment inflows. This indicator compares the company's current valuation with projected revenues, neutralizing short-term market noise and currency volatility to determine the fundamental trend of the long-term consensus business value.

Analysis of competing companies

Alcon - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio BLCO (Bausch & Lomb)|Glaukos Corp. - Forward P/S Multiple|Forward Price to Sales APLS (Apellis Corp)|BLTE: Forward P/S Multiple|Market Cap to Future Revenue Ratio ocutx.com (OCUL)|HROW (Harrow) - Forward P/S Multiple|Forward P/S Multiple Viridian Therapeutics Inc|Forward Price-to-Revenue Multiple LENZ (LENZ Pharma)|OCS (Oculis Pharma) - Forward Price to Sales|Price-to-Projected Revenue Ratio EyePoint Pharmaceuticals EYPT|kodiak.com - Price-to-Projected Revenue Ratio|Aldeyra - Forward P/S Multiple|Market Cap to Expected Sales Ratio KALA BIO, Inc. KALA|opusgtx.com (IRD) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple OKYO Pharma|ADVM (Adverum Biotechnologies Inc.) - Forward P/S Multiple|outlooktherapeutics.com (OTLK) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple CLSD (Clearside Biomedical, Inc.)|Price to Expected Revenue Ratio NBY|Forward P/S Multiple KPRX (Kiora Pharmaceuticals, Inc.)|Alimera Sciences Inc (ALIM) - Market Cap to Future Revenue Ratio|Eyenovia Corp - Forward P/S Multiple|GHSI (guardionhealth.com) - Market Cap to Projected Revenue|Ocuphire Pharma (OCUP) - Price-to-Projected Revenue Ratio